BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20531393)

  • 1. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.
    Biju K; Zhou Q; Li G; Imam SZ; Roberts JL; Morgan WW; Clark RA; Li S
    Mol Ther; 2010 Aug; 18(8):1536-44. PubMed ID: 20531393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term benefits of hematopoietic stem cell-based macrophage/microglia delivery of GDNF to the CNS in a mouse model of Parkinson's disease.
    Ge G; Sivasubramanian BP; Geng BD; Zhao S; Zhou Q; Huang G; O'Connor JC; Clark RA; Li S
    Gene Ther; 2024 May; 31(5-6):324-334. PubMed ID: 38627469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Biju KC; Santacruz RA; Chen C; Zhou Q; Yao J; Rohrabaugh SL; Clark RA; Roberts JL; Phillips KA; Imam SZ; Li S
    Neurosci Lett; 2013 Feb; 535():24-9. PubMed ID: 23295906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
    Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
    Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
    Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
    Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice.
    Chen C; Li X; Ge G; Liu J; Biju KC; Laing SD; Qian Y; Ballard C; He Z; Masliah E; Clark RA; O'Connor JC; Li S
    Sci Rep; 2018 Apr; 8(1):5460. PubMed ID: 29615705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatable Lentiviral Hematopoietic Stem Cell Gene Therapy in a Mouse Model of Parkinson's Disease.
    Ge G; Chen C; Guderyon MJ; Liu J; He Z; Yu Y; Clark RA; Li S
    Stem Cells Dev; 2018 Jul; 27(14):995-1005. PubMed ID: 29562865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.
    Tanriover G; Seval-Celik Y; Ozsoy O; Akkoyunlu G; Savcioglu F; Hacioglu G; Demir N; Agar A
    Folia Histochem Cytobiol; 2010 Sep; 48(3):434-41. PubMed ID: 21071351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electroacupuncture Therapy Ameliorates Motor Dysfunction via Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor in a Mouse Model of Parkinson's Disease.
    Pak ME; Ahn SM; Jung DH; Lee HJ; Ha KT; Shin HK; Choi BT
    J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):712-721. PubMed ID: 31644786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
    Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
    J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
    Mahato AK; Kopra J; Renko JM; Visnapuu T; Korhonen I; Pulkkinen N; Bespalov MM; Domanskyi A; Ronken E; Piepponen TP; Voutilainen MH; Tuominen RK; Karelson M; Sidorova YA; Saarma M
    Mov Disord; 2020 Feb; 35(2):245-255. PubMed ID: 31840869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo.
    Tomac A; Lindqvist E; Lin LF; Ogren SO; Young D; Hoffer BJ; Olson L
    Nature; 1995 Jan; 373(6512):335-9. PubMed ID: 7830766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective glial cell line-derived neurotrophic factor production in adult dopaminergic carotid body cells in situ and after intrastriatal transplantation.
    Villadiego J; Méndez-Ferrer S; Valdés-Sánchez T; Silos-Santiago I; Fariñas I; López-Barneo J; Toledo-Aral JJ
    J Neurosci; 2005 Apr; 25(16):4091-8. PubMed ID: 15843611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action.
    Schober A; Peterziel H; von Bartheld CS; Simon H; Krieglstein K; Unsicker K
    Neurobiol Dis; 2007 Feb; 25(2):378-91. PubMed ID: 17141511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.
    Gottschalk CG; Jana M; Roy A; Patel DR; Pahan K
    J Neurosci; 2021 Mar; 41(10):2287-2300. PubMed ID: 33514677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.
    Drinkut A; Tereshchenko Y; Schulz JB; Bähr M; Kügler S
    Mol Ther; 2012 Mar; 20(3):534-43. PubMed ID: 22086235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive, neuron-specific gene therapy by focused ultrasound-induced blood-brain barrier opening in Parkinson's disease mouse model.
    Lin CY; Hsieh HY; Chen CM; Wu SR; Tsai CH; Huang CY; Hua MY; Wei KC; Yeh CK; Liu HL
    J Control Release; 2016 Aug; 235():72-81. PubMed ID: 27235980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen Increases Striatal GDNF Immunoreactivity with no Effect on Striatal FGF-2 Immunoreactivity of MPTP-Treated Mice.
    Tripanichkul W; Jaroensuppaperch EO
    J Med Assoc Thai; 2015 Oct; 98 Suppl 9():S16-22. PubMed ID: 26817205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease.
    Dietz GP; Valbuena PC; Dietz B; Meuer K; Müeller P; Weishaupt JH; Bähr M
    Brain Res; 2006 Apr; 1082(1):61-6. PubMed ID: 16703672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.